Company Description
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally.
The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products.
It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands.
The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products.
This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals.
Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Sep 18, 2019 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 12,300 |
| CEO | Paul Keel |
Contact Details
Address: Building E, 200 South Kraemer Boulevard Brea, California 92821-6208 United States | |
| Phone | 714-817-7000 |
| Website | envistaco.com |
Stock Details
| Ticker Symbol | NVST |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $22.00 |
| CIK Code | 0001757073 |
| CUSIP Number | 29415F104 |
| ISIN Number | US29415F1049 |
| Employer ID | 83-2206728 |
| SIC Code | 3843 |
Key Executives
| Name | Position |
|---|---|
| Paul A. Keel | Chief Executive Officer and Director |
| Eric D. Hammes | Senior Vice President and Chief Financial Officer |
| Mark E. Nance J.D. | Senior Vice President, General Counsel and Secretary |
| Mischa M. Reis | Senior Vice President of Strategy and Corporate Development |
| Robert Befidi Jr. | President of Diagnostics |
| Faez Kaabi | Vice President, Chief Accounting Officer and Corporate Controller |
| Andrew Chen | Chief Information Officer |
| Jim Gustafson | Vice President of Investor Relations |
| Paul Sumilas | Chief Compliance Officer |
| Suraj Satpathy | Chief Human Resources officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 25, 2025 | 144 | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 5, 2025 | SCHEDULE 13G | Filing |
| Aug 1, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jul 31, 2025 | 10-Q | Quarterly Report |
| Jul 31, 2025 | 8-K | Current Report |
| Jul 16, 2025 | 8-K | Current Report |
| Jul 15, 2025 | SCHEDULE 13G | Filing |
| Jun 12, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 11-K | Annual report of employee stock purchase, savings and similar plans |